ANALYSIS: Are Prediction Markets Turning Brokers Into Bookies? Regeneron stock jumped on Tuesday after the biotech company reported adjusted earnings of $11.83 per share on$3.75 billion in third-quarter sales. Analysts polled by FactSet expected Regeneron Pharmaceuticals (REGN) to earn $9.65 a share and report$3.59 billion in sales. Notably, third-quarter earnings took a 68-cent hit thanks to a tax charge, and still came in well above forecasts. YOU MAY ALSO LIKE: GSK Crumbles As Blood Cancer Comeback Fa ...